PATIENT FOCUSED, EVIDENCE-BASED APPROACH

NYTV VIRTUAL 2020

THURSDAY, DECEMBER 10th, 2020

COURSE DIRECTORS
Samin K. Sharma, MD, FACC, MSCAI
Annapoorna S. Kini, MD, MRCP, FACC
Gilbert H. Tang, MD, MSc, MBA, FRCSC, FACC
Stamatios Lerakis, MD, PhD, FACC, FASE, FSCCT
Roxana Mehran, MD, FACC, FACP, FESC, MSCAI

Follow Us @NYTV_Live
#nytvvirtual
#nytv2020

Register Online
www.nytranscathetervalves.org
PROGRAM OVERVIEW

Structural heart disease refers to a defect in the heart’s valves, walls, or chambers. The most common types of structural heart disease are aortic valve disease, mitral valve disease, tricuspid and pulmonic valve disease, hypertrophic cardiomyopathy and congenital heart disease, such as atrial septal defect and ventricular septal defect.

This New York Transcatheter Valves course is poised to help healthcare professionals stay current on new and emerging approaches in the diagnosis, management and treatment of valvular and structural heart disease. A robust agenda combines individual and collective opinions from field expert clinicians and scholars. The educational format will consist of recorded lectures, live transcatheter procedures with moderated discussions and live interactive Q&A’s with our expert faculty.

TARGET AUDIENCE

This course is specifically designed for:
Interventional Cardiologists, Invasive Cardiologists, Cardiothoracic Surgeons, Interventional Radiologists, Interventional Fellows in Training, Nurses, Technicians and other Allied Health Care Professionals who work in Structural Heart Disease.

LEARNING OBJECTIVES

- Appraise new and upcoming technologies in the management of structural heart disease to determine their benefit for patients.
- Present indications, techniques, outcomes, and complications for transcatheter valve intervention in patients with native valve disease and bioprosthetic valve dysfunction.
- Evaluate the rationale, challenges, and necessity of the heart team approach to valvular heart disease, and the functionality of the team within a center of excellence.
- Assess the barriers to care in patients with valvular heart disease with specific attention to current gaps in the timely delivery of percutaneous and surgical interventions.

ACCREDITATION

The Icahn School of Medicine at Mount Sinai is accredited by the Accreditation Council for Continuing Medical Education to provide Continuing Medical Education for physicians.

CREDIT DESIGNATION

The Icahn School of Medicine at Mount Sinai designates this live activity for a maximum of 5.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

VERIFICATION OF ATTENDANCE

Verification of attendance will be provided to all professionals.

CONFERENCE INFORMATION

For additional information, please email cme@mssm.edu.

REGISTRATION FEES

This course will be complimentary but, if you would like to claim CME credit, there is a $25 fee.

REGISTER ONLINE

www.nytranscathetervalves.org
AGENDA

8:00 – 8:05am
WELCOME & INTRODUCTION
Annapoorna S. Kini, MD; Stamatios Lerakis, MD; Roxana Mehran, MD; Samin K. Sharma, MD; Gilbert Tang, MD

8:05 – 8:30am
Top Ten Advances in Transcatheter Valve Therapy 2020
Samin K. Sharma, MD

8:30 – 8:55am
KEYNOTE LECTURE
Valvular Heart Disease in the COVID Era: The Path Forward
Patrick T. O’Gara, MD

SESSION 1: TAVR HOT TOPICS IN 2020 AND FUTURE DIRECTIONS
Moderator: Roxana Mehran, MD

8:55 – 9:20am
LIVE CASE #1
Operators: Samin K. Sharma, MD; Annapoorna S. Kini, MD; Gilbert Tang, MD; Stamatios Lerakis, MD
Panelists: Alexandre Abizaid, MD; Samir Kapadia, MD; Michael Mack, MD; Didier Tchètchè, MD

9:20 – 9:30am
Adapting to Change in Structural Heart Disease Training
Michael Mack, MD

9:30 – 9:40am
Current Update on Next Generation TAVR Valves
Alexandre Abizaid, MD

9:40 – 9:50am
TAVR in Bicuspid Valve
Raj Makkar, MD

9:50 – 10:00am
TAVR in Small Annulus: The SMART Trial
Howard C. Herrmann, MD

10:00 – 10:10am
Neuro-Protection in TAVR: Is it Effective?
Samir Kapadia, MD

10:10 – 10:20am
Update on Pharmacology Post TAVR: Future Directions
George Dangas, MD

10:20 – 10:30am
TAVR and CAD: Rationale and Design of the COMPLETE TAVR Trial
David E. Wood, MD

10:30 – 10:40am
Failed TAVR: Results from Surgical Explants
Vinod Thourani, MD

10:40 – 10:50am
Coronary Access Post TAVR: TAVRCathAID
Annapoorna S. Kini, MD

10:50 – 11:05am
LIVE ROUND TABLE Q&A
Alexandre Abizaid, MD; George Dangas, MD; Howard C. Herrmann, MD; Samir Kapadia, MD; Raj Makkar, MD; Patrick T. O’Gara, MD; Vinod Thourani, MD; David E. Wood, MD

11:05 – 11:35am
LIVE CASE #2
Moderator: George Dangas, MD
Operators: Samin K. Sharma, MD; Annapoorna S. Kini, MD; Gilbert Tang, MD; Stamatios Lerakis, MD
Panelists: Howard C. Herrmann, MD; Saibal Kar, MD; Raj Makkar, MD; Vinod Thourani, MD; David E. Wood, MD

REGISTER ONLINE
www.nytranscathetervalves.org
SESSION 2: TMVR: HOT TOPICS IN 2020 AND FUTURE DIRECTIONS
Moderator: Eberhard Grube, MD

11:45 – 12:00pm
Next Generation Mitral Devices for Repair/Replacement
Eberhard Grube, MD

12:00 – 12:15pm
Update on Mitral Clip: COAPT and More
Gregg Stone, MD

12:15 – 12:35pm
LIVE ROUND TABLE Q&A
Saibal Kar, MD and Gregg Stone, MD

SESSION 3: TRICUSPID VALVE: NOT FORGOTTEN, FRONT AND CENTER

12:35 – 12:50pm
Tricuspid Valve Disease: Pathophysiology and Evolving Therapies
Saibal Kar, MD

12:50 – 1:05pm
Planning and Results of Transcatheter Tricuspid Valve Therapy
Didier Tchètchè, MD

1:05 – 1:25pm
LIVE Q&A
Alexandre Abizaid, MD; Howard C. Herrmann, MD; Eberhard Grube, MD; Samir Kapadia, MD; Saibal Kar, MD; Annapoorna S. Kini, MD; Stamatios Lerakis, MD; Raj Makkar, MD; Roxana Mehran, MD; Samin K. Sharma, MD; Gregg Stone, MD; Gilbert Tang, MD; Didier Tchètchè, MD; Vinod Thourani, MD; David E. Wood, MD

1:25 – 1:30pm
CONCLUSION
Annapoorna S. Kini, MD; Stamatios Lerakis, MD; Roxana Mehran, MD; Samin K. Sharma, MD; Gilbert Tang, MD

FACULTY DISCLOSURE
It is the policy of ISMMS to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. Presenters must also make a meaningful disclosure to the audience of their discussions of unlabeled or unapproved drugs or devices. This information will be available as part of the course material.
FACULTY

COURSE DIRECTORS

Samin K. Sharma, MD, FACC, MSCAI
Senior Vice President, Operations & Quality, Mount Sinai Heart
Director, Interventional Cardiology, Mount Sinai Health System
Anandi Lal Sharma Professor of Medicine (Cardiology)

Annapoorna S. Kini, MD, MRCP, FACC
Director, Cardiac Catheterization Laboratory
Director, Structural Heart Disease Program
Zena and Michael A. Weiner Professor of Medicine

Gilbert H. Tang, MD, MSc, MBA, FRCSC, FACC
Surgical Director, Structural Heart Program
Associate Professor Cardiovascular Surgery

Stamatios A. Lerakis, MD, PhD, FACC, FASE, FSCCT
Director of Noninvasive Cardiology
Director of Imaging for Structural and Valve Interventions
Professor of Medicine

Roxana Mehran, MD, FACC, FACP, FESC, MSCAI
Director, Interventional Cardiovascular Research and Clinical Trials
Professor of Medicine (Cardiology)
Professor of Population Health Science and Policy

MOUNT SINAI FACULTY

George D. Dangas, MD, PhD, FACC, MSCAI
Director, Cardiovascular Innovation
Professor of Medicine (Cardiology)
Professor of Surgery (Vascular)

Gregg W. Stone, MD
Director of Academic Affairs for the Mount Sinai Heart Health System
Professor of Medicine (Cardiology)

GUEST FACULTY

Alexandre Abizaid, MD, PhD, FACC
Director of Interventional Cardiology
Dante Pazzanese Institute of Cardiology
São Paulo, Brazil

Eberhard Grube, MD, FSCAI
Head CiIC
University Hospital Bonn
Bonn, Germany

Howard C. Herrmann, MD
Health System Director for Interventional Cardiology
Director, Cardiac Catheterization Lab
Hospital of the University of Pennsylvania
Philadelphia, PA

Samir Kapadia, MD
Chairman of the Department of CV Medicine
Professor of Medicine
Cleveland Clinic
Cleveland, Ohio

Saibal Kar, MD, FACC, FSCAI
Director of Structural Heart Disease and Research
HCA Healthcare
Los Angeles, CA

Michael J. Mack, MD
Medical Director of Cardiovascular Services
Chairman of the BSW The Heart Hospital
Baylor Scott & White Health System
Dallas, TX

Raj Makkar, FACC, FSCAI
Vice President of Cardiovascular Innovation
Executive Director, Cardiac Interventional Services
Director, Interventional Cardiology Research Program
Cedars-Sinai Hospital
Los Angeles, CA

Patrick T. O’Gara, MD
Director of Strategic Planning, Division of CV Medicine
Watkins Family Distinguished Chair in Cardiology
Brigham and Women’s Hospital
Boston, MA

Didier Tchétché, MD, PhD
Director of the Structural Heart Disease Department
Clinique Pasteur
Toulouse, France

Vinod Thourani, MD
Department of Cardiovascular Surgery
Marcus Heart and Vascular Center
Piedmont Heart Institute
Atlanta, GA

David Wood, MD, FRCPC, FACC, FESC
Director, Centre for Cardiovascular Innovation
Head, Division of Cardiology and Medical Director, Professor, University of British Columbia
Vancouver, Canada